{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T20:30:07Z","timestamp":1773088207387,"version":"3.50.1"},"reference-count":26,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T00:00:00Z","timestamp":1712275200000},"content-version":"vor","delay-in-days":105,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010804","name":"Faculty of Medicine, Prince of Songkla University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010804","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,12,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Chronic hepatitis B (CHB) significantly impacts the health-related quality of life (HRQoL), but remains underexplored in the Thai population. Health state utilities (HSU) are indicators reflecting HRQoL which serve as fundamental inputs for economic evaluation analyses. This study aimed at assessing differences in HRQoL across five CHB stages in Thai patients, including non-cirrhotic CHB, compensated cirrhosis, decompensated cirrhosis, early-\/intermediate-stage hepatocellular carcinoma (HCC) and advanced-\/terminal-stage HCC.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We conducted a cross-sectional study to collect HRQoL data from patients with CHB at five stages. The study included patients with CHB who were followed up at a super-tertiary care centre between March 2021 and February 2022. The participants completed the EQ-5D-5L questionnaire and provided demographic data. Disease stage and relevant data were obtained from medical records. HSU and Euroqol-visual analogue scale (EQ-VAS) scores, calculated using Thai-specific conversion coefficients, were assessed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Among 422 patients, 236 did not have cirrhosis, 92 had compensated cirrhosis, 13 had decompensated cirrhosis, 55 had early-\/intermediate-stage HCC, and 26 had advanced-\/terminal-stage HCC. The HSU scores for non-cirrhotic, compensated cirrhosis, decompensated cirrhosis, early-\/intermediate-stage HCC and advanced-\/terminal-stage HCC were 0.95\u2009\u00b1\u20090.08, 0.89\u2009\u00b1\u20090.16, 0.79\u2009\u00b1\u20090.19, 0.89\u2009\u00b1\u20090.12 and 0.52\u2009\u00b1\u20090.39, respectively. Similarly, the EQ-VAS scores for various CHB stages were 83.56\u2009\u00b1\u200912.90, 80.48\u2009\u00b1\u200913.03, 68.76\u2009\u00b1\u200917.40, 79.00\u2009\u00b1\u200914.38 and 62.92\u2009\u00b1\u200920.62, respectively. A significant correlation (r\u2009=\u20090.469, P\u2009&amp;lt;\u20090.001) was observed between the HSU and EQ-VAS scores. The disease progression led to a notable HSU decline, particularly in the advanced-\/terminal-stage HCC group (regression coefficient: \u20130.436, P\u2009&amp;lt;\u20090.001). The EQ-VAS scores indicated reduced quality of life in advanced liver disease.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Later CHB stages compromise the HRQoL. Decompensated cirrhosis and advanced-\/terminal-stage HCC profoundly affect physical health and quality of life, whereas patients with compensated cirrhosis and early-\/intermediate-stage HCC report better HRQoL.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/gastro\/goae015","type":"journal-article","created":{"date-parts":[[2024,4,6]],"date-time":"2024-04-06T00:52:59Z","timestamp":1712364779000},"source":"Crossref","is-referenced-by-count":6,"title":["Health-related quality of life in Thai patients with chronic hepatitis B"],"prefix":"10.1093","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-7949-0211","authenticated-orcid":false,"given":"Ratthanan","family":"Chantrakul","sequence":"first","affiliation":[{"name":"Gastroenterology and Hepatology Unit, Division of Internal Medicine, Faculty of Medicine, Prince of Songkla University , Songkhla, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0007-8214","authenticated-orcid":false,"given":"Pimsiri","family":"Sripongpun","sequence":"additional","affiliation":[{"name":"Gastroenterology and Hepatology Unit, Division of Internal Medicine, Faculty of Medicine, Prince of Songkla University , Songkhla, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6582-9608","authenticated-orcid":false,"given":"Tanawat","family":"Pattarapuntakul","sequence":"additional","affiliation":[{"name":"Gastroenterology and Hepatology Unit, Division of Internal Medicine, Faculty of Medicine, Prince of Songkla University , Songkhla, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5753-7939","authenticated-orcid":false,"given":"Naichaya","family":"Chamroonkul","sequence":"additional","affiliation":[{"name":"Gastroenterology and Hepatology Unit, Division of Internal Medicine, Faculty of Medicine, Prince of Songkla University , Songkhla, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3364-0664","authenticated-orcid":false,"given":"Chanon","family":"Kongkamol","sequence":"additional","affiliation":[{"name":"Division of Family and Preventive Medicine, Faculty of Medicine, Prince of Songkla University , Songkhla, Thailand"},{"name":"Division of Digital Innovation and Data Analytics, Faculty of Medicine, Prince of Songkla University , Songkhla, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1995-4405","authenticated-orcid":false,"given":"Pochamana","family":"Phisalprapa","sequence":"additional","affiliation":[{"name":"Division of Ambulatory Medicine, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University , Bangkok, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4058-5977","authenticated-orcid":false,"given":"Apichat","family":"Kaewdech","sequence":"additional","affiliation":[{"name":"Gastroenterology and Hepatology Unit, Division of Internal Medicine, Faculty of Medicine, Prince of Songkla University , Songkhla, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,4,5]]},"reference":[{"key":"2024040523414437500_goae015-B1","doi-asserted-by":"crossref","first-page":"e00046-19","DOI":"10.1128\/CMR.00046-19","article-title":"Hepatitis B virus: advances in prevention, diagnosis, and therapy","volume":"33","author":"Nguyen","year":"2020","journal-title":"Clin Microbiol Rev"},{"key":"2024040523414437500_goae015-B2","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.4269\/ajtmh.21-0283","article-title":"Hepatitis B transmission: is vertical transmission the major route in intermediate endemic areas? A proof-of-concept study based on mother-child genotypes","volume":"105","author":"Poddar","year":"2021","journal-title":"Am J Trop Med Hyg"},{"key":"2024040523414437500_goae015-B3"},{"key":"2024040523414437500_goae015-B4","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/s41575-023-00760-9","article-title":"Global burden of hepatitis B virus: current status, missed opportunities and a call for action","volume":"20","author":"Hsu","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2024040523414437500_goae015-B5","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1016\/S0140-6736(15)61412-X","article-title":"Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013","volume":"386","author":"Schweitzer","year":"2015","journal-title":"Lancet"},{"key":"2024040523414437500_goae015-B6","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ijid.2016.08.017","article-title":"Prevalence of chronic hepatitis B virus infection in Thailand: a systematic review and meta-analysis","volume":"51","author":"Leroi","year":"2016","journal-title":"Int J Infect Dis"},{"key":"2024040523414437500_goae015-B7","doi-asserted-by":"crossref","first-page":"e0270458","DOI":"10.1371\/journal.pone.0270458","article-title":"HBV seroprevalence and liver fibrosis status among population born before national immunization in Southern Thailand: Findings from a health check-up program","volume":"17","author":"Sono","year":"2022","journal-title":"PLoS One"},{"key":"2024040523414437500_goae015-B8","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/S0140-6736(22)01200-4","article-title":"Hepatocellular carcinoma","volume":"400","author":"Vogel","year":"2022","journal-title":"Lancet"},{"key":"2024040523414437500_goae015-B9","doi-asserted-by":"crossref","first-page":"e00310","DOI":"10.14309\/ctg.0000000000000310","article-title":"Validation of the \u201csix-and-twelve\u201d prognostic score in transarterial chemoembolization-treated hepatocellular carcinoma patients","volume":"12","author":"Kaewdech","year":"2021","journal-title":"Clin Transl Gastroenterol"},{"key":"2024040523414437500_goae015-B10","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ejim.2019.09.004","article-title":"Health-related quality of life in patients with compensated and decompensated liver cirrhosis","volume":"70","author":"Labenz","year":"2019","journal-title":"Eur J Intern Med"},{"key":"2024040523414437500_goae015-B11","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s13561-020-00270-3","article-title":"Preference-based measures of health-related quality of life in congenital mobility impairment: a systematic review of validity and responsiveness","volume":"10","author":"Bray","year":"2020","journal-title":"Health Econ Rev"},{"key":"2024040523414437500_goae015-B12","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s41669-022-00380-0","article-title":"Mapping of the World Health Organization Quality of Life Brief (WHOQOL-BREF) to the EQ-5D-5L in the general Thai population","volume":"7","author":"Kangwanrattanakul","year":"2023","journal-title":"Pharmacoecon Open"},{"key":"2024040523414437500_goae015-B13","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection","volume":"67","author":"European Association for the Study of the Liver","year":"2017","journal-title":"J Hepatol"},{"key":"2024040523414437500_goae015-B14","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"2024040523414437500_goae015-B15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","article-title":"Asian-pacific clinical practice guidelines on the management of hepatitis B: a 2015 update","volume":"10","author":"Sarin","year":"2016","journal-title":"Hepatol Int"},{"key":"2024040523414437500_goae015-B16","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"EASL clinical practice guidelines: management of hepatocellular carcinoma","volume":"69","author":"Galle","year":"2018","journal-title":"J Hepatol"},{"key":"2024040523414437500_goae015-B17","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1097\/HEP.0000000000000466","article-title":"AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma","volume":"78","author":"Singal","year":"2023","journal-title":"Hepatology"},{"key":"2024040523414437500_goae015-B18","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s12072-017-9799-9","article-title":"Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update","volume":"11","author":"Omata","year":"2017","journal-title":"Hepatol Int"},{"key":"2024040523414437500_goae015-B19","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","article-title":"BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update","volume":"76","author":"Reig","year":"2022","journal-title":"J Hepatol"},{"key":"2024040523414437500_goae015-B20","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.jhep.2018.03.024","article-title":"EASL clinical practice guidelines for the management of patients with decompensated cirrhosis","volume":"69","author":"Angeli","year":"2018","journal-title":"J Hepatol"},{"key":"2024040523414437500_goae015-B21","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","article-title":"Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)","volume":"20","author":"Herdman","year":"2011","journal-title":"Qual Life Res"},{"key":"2024040523414437500_goae015-B22","author":"Pattanaphesaj","year":"2014"},{"key":"2024040523414437500_goae015-B23","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1155\/2012\/736452","article-title":"Health state utilities and quality of life in patients with hepatitis B","volume":"26","author":"Woo","year":"2012","journal-title":"Can J Gastroenterol"},{"key":"2024040523414437500_goae015-B24","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1002\/hep.22138","article-title":"Health-related quality of life in chronic hepatitis B patients","volume":"47","author":"Ong","year":"2008","journal-title":"Hepatology"},{"key":"2024040523414437500_goae015-B25","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1080\/14737167.2018.1494574","article-title":"The EQ-5D-5L valuation study in Thailand","volume":"18","author":"Pattanaphesaj","year":"2018","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"2024040523414437500_goae015-B26","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1007\/s11136-013-0537-z","article-title":"Assessing the performance of the EQ-VAS in the NHS PROMs programme","volume":"23","author":"Feng","year":"2014","journal-title":"Qual Life Res"}],"container-title":["Gastroenterology Report"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/gastro\/article-pdf\/doi\/10.1093\/gastro\/goae015\/57173819\/goae015.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/gastro\/article-pdf\/doi\/10.1093\/gastro\/goae015\/57173819\/goae015.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,6]],"date-time":"2024-04-06T00:53:09Z","timestamp":1712364789000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/gastro\/article\/doi\/10.1093\/gastro\/goae015\/7641556"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,22]]},"references-count":26,"URL":"https:\/\/doi.org\/10.1093\/gastro\/goae015","relation":{},"ISSN":["2052-0034"],"issn-type":[{"value":"2052-0034","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,1,1]]},"published":{"date-parts":[[2023,12,22]]},"article-number":"goae015"}}